Literature DB >> 23335373

Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.

Sébastien Malinge1, Clarisse Thiollier, Timothy M Chlon, Louis C Doré, Lauren Diebold, Olivier Bluteau, Vinciane Mabialah, William Vainchenker, Philippe Dessen, Susan Winandy, Thomas Mercher, John D Crispino.   

Abstract

The transcription factor Ikaros regulates the development of hematopoietic cells. Ikaros-deficient animals fail to develop B cells and display a T-cell malignancy, which is correlated with altered Notch signaling. Recently, loss of Ikaros was associated with progression of myeloproliferative neoplasms to acute myeloid leukemia and increasing evidence shows that Ikaros is also critical for the regulation of myeloid development. Previous studies showed that Ikaros-deficient mice have increased megakaryopoiesis, but the molecular mechanism of this phenomenon remains unknown. Here, we show that Ikaros overexpression decreases NOTCH-induced megakaryocytic specification, and represses expression of several megakaryocytic genes including GATA-1 to block differentiation and terminal maturation. We also demonstrate that Ikaros expression is differentially regulated by GATA-2 and GATA-1 during megakaryocytic differentiation and reveal that the combined loss of Ikzf1 and Gata1 leads to synthetic lethality in vivo associated with prominent defects in erythroid cells and an expansion of megakaryocyte progenitors. Taken together, our observations demonstrate an important functional interplay between Ikaros, GATA factors, and the NOTCH signaling pathway in specification and homeostasis of the megakaryocyte lineage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335373      PMCID: PMC3612856          DOI: 10.1182/blood-2012-08-450627

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Ikaros regulates neutrophil differentiation.

Authors:  Alexis Dumortier; Peggy Kirstetter; Philippe Kastner; Susan Chan
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

2.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

3.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

Authors:  R Jäger; H Gisslinger; F Passamonti; E Rumi; T Berg; B Gisslinger; D Pietra; A Harutyunyan; T Klampfl; D Olcaydu; M Cazzola; R Kralovics
Journal:  Leukemia       Date:  2010-05-27       Impact factor: 11.528

4.  Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow.

Authors:  N Debili; L Coulombel; L Croisille; A Katz; J Guichard; J Breton-Gorius; W Vainchenker
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

5.  Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages.

Authors:  Yojiro Arinobu; Shin-ichi Mizuno; Yong Chong; Hirokazu Shigematsu; Tadafumi Iino; Hiromi Iwasaki; Thomas Graf; Robin Mayfield; Susan Chan; Philippe Kastner; Koichi Akashi
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

6.  Regulator of myeloid differentiation and function: The secret life of Ikaros.

Authors:  Olivia L Francis; Jonathon L Payne; Rui-Jun Su; Kimberly J Payne
Journal:  World J Biol Chem       Date:  2011-06-26

7.  A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development.

Authors:  R A Shivdasani; Y Fujiwara; M A McDevitt; S H Orkin
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

8.  Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1.

Authors:  P Zhang; G Behre; J Pan; A Iwama; N Wara-Aswapati; H S Radomska; P E Auron; D G Tenen; Z Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  GATA-2 reinforces megakaryocyte development in the absence of GATA-1.

Authors:  Zan Huang; Louis C Dore; Zhe Li; Stuart H Orkin; Gang Feng; Simon Lin; John D Crispino
Journal:  Mol Cell Biol       Date:  2009-07-20       Impact factor: 4.272

10.  Ikaros regulates Notch target gene expression in developing thymocytes.

Authors:  Sheila Chari; Susan Winandy
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

View more
  23 in total

1.  Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.

Authors:  David Boutboul; Hye Sun Kuehn; Zoé Van de Wyngaert; Julie E Niemela; Isabelle Callebaut; Jennifer Stoddard; Christelle Lenoir; Vincent Barlogis; Catherine Farnarier; Frédéric Vely; Nao Yoshida; Seiji Kojima; Hirokazu Kanegane; Akihiro Hoshino; Fabian Hauck; Ludovic Lhermitte; Vahid Asnafi; Philip Roehrs; Shaoying Chen; James W Verbsky; Katherine R Calvo; Ammar Husami; Kejian Zhang; Joseph Roberts; David Amrol; John Sleaseman; Amy P Hsu; Steven M Holland; Rebecca Marsh; Alain Fischer; Thomas A Fleisher; Capucine Picard; Sylvain Latour; Sergio D Rosenzweig
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

2.  Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.

Authors:  David H Murray; Erin L Symonds; Graeme P Young; Susan Byrne; Philippa Rabbitt; Amitesh Roy; Kathryn Cornthwaite; Christos S Karapetis; Susanne K Pedersen
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-10       Impact factor: 4.553

3.  Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia.

Authors:  Jasmijn D E de Rooij; Eva Beuling; Marry M van den Heuvel-Eibrink; Askar Obulkasim; André Baruchel; Jan Trka; Dirk Reinhardt; Edwin Sonneveld; Brenda E S Gibson; Rob Pieters; Martin Zimmermann; C Michel Zwaan; Maarten Fornerod
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

4.  Normal hematologic parameters and fetal hemoglobin silencing with heterozygous IKZF1 mutations.

Authors:  Nour Abdulhay; Claudia Fiorini; Attila Kumánovics; Ashleigh A Sun; Jeannette Hansen-Rejali; Karl V Voelkerding; Sergio D Rosenzweig; Harry R Hill; Vijay G Sankaran
Journal:  Blood       Date:  2016-08-31       Impact factor: 22.113

5.  Direct protein interactions are responsible for Ikaros-GATA and Ikaros-Cdk9 cooperativeness in hematopoietic cells.

Authors:  Stefania Bottardi; Lionel Mavoungou; Vincent Bourgoin; Nazar Mashtalir; El Bachir Affar; Eric Milot
Journal:  Mol Cell Biol       Date:  2013-06-03       Impact factor: 4.272

Review 6.  Platelets and cancer: a casual or causal relationship: revisited.

Authors:  David G Menter; Stephanie C Tucker; Scott Kopetz; Anil K Sood; John D Crissman; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

7.  Regulation of RNA polymerase II activity is essential for terminal erythroid maturation.

Authors:  Zachary C Murphy; Kristin Murphy; Jacquelyn Myers; Michael Getman; Tyler Couch; Vincent P Schulz; Kimberly Lezon-Geyda; Cal Palumbo; Hongxia Yan; Narla Mohandas; Patrick G Gallagher; Laurie A Steiner
Journal:  Blood       Date:  2021-11-04       Impact factor: 22.113

Review 8.  IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.

Authors:  Hye Sun Kuehn; Cristiane J Nunes-Santos; Sergio D Rosenzweig
Journal:  J Clin Immunol       Date:  2021-01-03       Impact factor: 8.317

Review 9.  Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology.

Authors:  Hye Sun Kuehn; Cristiane J Nunes-Santos; Sergio D Rosenzweig
Journal:  Expert Rev Clin Immunol       Date:  2021-03-19       Impact factor: 4.473

Review 10.  Long and short non-coding RNAs as regulators of hematopoietic differentiation.

Authors:  Franck Morceau; Sébastien Chateauvieux; Anthoula Gaigneaux; Mario Dicato; Marc Diederich
Journal:  Int J Mol Sci       Date:  2013-07-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.